SCHEMBL472171

SCHEMBL472171

[CH2]COCC1CC=CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
LMNA P02545 4/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36
CCNA2 P20248 2/20 0.36
CDK2 P24941 2/20 0.36
CCNA1 P78396 2/20 0.36
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
APOBEC3A P31941 2/20 0.33
APOBEC3G Q9HC16 2/20 0.33
RGS12 O14924 2/20 0.33
KDM4E B2RXH2 2/20 0.33
PABPC1 P11940 1/20 0.33
EIF4H Q15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7973683 0.87 MAPK1 (0.56) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL7260723 0.83 MAPK1 (0.49) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL12286212 0.79 MAPK1 (0.46) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL16480957 0.79 MAPK1 (0.46) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL14241127 0.79 MAPK1 (0.46) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL7927729 0.79 ALDH1A1 (0.44) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL19695510 0.79 ALDH1A1 (0.44) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL13895288 0.76 MAPK1 (0.44) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL19695304 0.76 MAPK1 (0.41) MAPK1LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL19695484 0.76 MAPK1 (0.41) MAPK1LMNAALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466303-B2 Process for production of epoxy compound SHOWA DENKO K.K. (JP) 2013-06-18 US disclosed
US-20120029217-A1 PROCESS FOR PRODUCING EPOXY COMPOUND SHOWA DENKO K.K. (JP) 2012-02-02 US disclosed
EP-2412712-A1 METHOD FOR PRODUCING EPOXY COMPOUND Showa Denko K.K. (JP) 2012-02-01 EP disclosed
US-20110009652-A1 PROCESS FOR PRODUCTION OF EPOXY COMPOUND SHOWA DENKO KK (JP) 2011-01-13 US disclosed
EP-2261219-A1 PROCESS FOR PRODUCTION OF EPOXY COMPOUND Showa Denko K.K. (JP) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029217-A1 PROCESS FOR PRODUCING EPOXY COMPOUND NOX4, NOX5, NOXO1 MAPK1 1102/4885LMNA 4828/4885ALDH1A1 1104/4885
US-20110009652-A1 PROCESS FOR PRODUCTION OF EPOXY COMPOUND DUOX2, EPX, DUOX1 MAPK1 1812/4885LMNA 4681/4885ALDH1A1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.